Grail's Galleri Screens for 50 Cancers. Insurers Won't Pay Yet

Grail's Galleri test can screen for 50 cancers from a single blood draw — but the question of whether Medicare and other health insurers will cover it now hinges on FDA approval.

That approval case just got harder to make. A major study of the test failed to prove that Galleri could detect later-stage cancers, according to the source report on the findings.

The stakes are straightforward. Galleri is a multi-cancer early detection test built to find malignancies across 50 cancer types from one blood sample. Its commercial future depends less on the technology itself than on who pays for it. Private insurers and Medicare — the U.S. government program covering roughly 66 million older Americans — set coverage terms largely around regulatory milestones, and full FDA approval sits at the center of that decision tree.

The failed endpoint matters because late-stage detection is where a blood-based screen faces its most direct competition from established diagnostics — and where proving clinical value is essential to winning broad reimbursement.

For Grail, the path forward runs through the FDA. Regulators will weigh the study results as the company seeks approval. Insurers, in turn, will weigh the FDA's decision as they determine whether Galleri becomes a covered benefit or stays a product patients pay for largely out of pocket.

The so-what for the diagnostics market: a test that promises to find 50 cancers from one blood draw remains, for now, a technology whose reach is limited by evidence — and by a payment system that will not move ahead of the regulator.